SCHEMBL5134641

SCHEMBL5134641

CCCCN(Cc1ccc(F)c(C(F)(F)F)c1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.45
CRHR1 P34998 5/20 0.41
TSHR P16473 3/20 0.37
UBE2M P61081 1/20 0.37
DCUN1D1 Q96GG9 1/20 0.37
BCHE P06276 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
NR1H3 Q13133 1/20 0.36
P2RX7 Q99572 1/20 0.35
HSD11B1 P28845 1/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP3A4 P08684 2/20 0.35
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
HDAC1 Q13547 1/20 0.34
ATP4A P20648 1/20 0.34
ATP4B P51164 1/20 0.34
CXCR3 P49682 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135207 0.96 C5AR1 (0.42) C5AR1CRHR1TSHRUBE2MDCUN1D1
SCHEMBL649437 0.94 C5AR1 (0.46) C5AR1CRHR1TSHRUBE2MDCUN1D1
SCHEMBL650883 0.93 C5AR1 (0.45) C5AR1CRHR1TSHRBCHEHSD11B1
SCHEMBL5137867 0.91 C5AR1 (0.48) C5AR1CRHR1TSHRBCHEP2RX7
SCHEMBL649008 0.90 C5AR1 (0.45) C5AR1CRHR1TSHRBCHEHSD11B1
SCHEMBL5136054 0.89 C5AR1 (0.42) C5AR1TSHRUBE2MDCUN1D1BCHE
SCHEMBL648035 0.88 C5AR1 (0.46) C5AR1CRHR1TSHRUBE2MDCUN1D1
SCHEMBL648706 0.88 C5AR1 (0.46) C5AR1CRHR1TSHRBCHEHSD11B1
SCHEMBL652185 0.87 C5AR1 (0.63) C5AR1TSHRUBE2MDCUN1D1KDM4E
SCHEMBL5135213 0.87 C5AR1 (0.42) C5AR1CRHR1TSHRUBE2MDCUN1D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed